177 related articles for article (PubMed ID: 34048072)
1. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.
Piciocchi A; Messina M; Elia L; Vitale A; Soddu S; Testi AM; Chiaretti S; Mancini M; Albano F; Spadano A; Krampera M; Bonifacio M; Cairoli R; Vetro C; Colella F; Ferrara F; Cimino G; Bassan R; Fazi P; Vignetti M
Am J Hematol; 2021 Sep; 96(9):E334-E338. PubMed ID: 34048072
[No Abstract] [Full Text] [Related]
2. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
[No Abstract] [Full Text] [Related]
3. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
Moorman AV; Barretta E; Butler ER; Ward EJ; Twentyman K; Kirkwood AA; Enshaei A; Schwab C; Creasey T; Leongamornlert D; Papaemmanuil E; Patrick P; Clifton-Hadley L; Patel B; Menne T; McMillan AK; Harrison CJ; Rowntree CJ; Marks DI; Fielding AK
Leukemia; 2022 Mar; 36(3):625-636. PubMed ID: 34657128
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
[TBL] [Abstract][Full Text] [Related]
5. Mixed-phenotype acute leukemia with t(4;11)(q21;q23)
Liu H
Blood; 2019 Mar; 133(11):1265. PubMed ID: 30872272
[No Abstract] [Full Text] [Related]
6. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
[TBL] [Abstract][Full Text] [Related]
7. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
[TBL] [Abstract][Full Text] [Related]
8. A novel KMT2A-ACTN2 fusion in infant B-cell acute lymphoblastic leukemia.
Yoshida M; Nakabayashi K; Ogata-Kawata H; Osumi T; Tsujimoto SI; Shirai R; Yoshida K; Okamura K; Matsumoto K; Kiyokawa N; Tomizawa D; Hata K; Kato M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27821. PubMed ID: 31115144
[No Abstract] [Full Text] [Related]
9. Osteopontin-c is overexpressed in KMT2A-AFF1 positive pediatric B-cell lymphoblastic leukemia when compared to those with ETV6-RUNX1".
da Fonseca Bastos ACS; da Silva Rezende AC; Ferreira LB; Blunck CB; Pombo-de-Oliveira MS; Emerenciano M; Gimba ERP
Leuk Res; 2020 Apr; 91():106316. PubMed ID: 32114371
[No Abstract] [Full Text] [Related]
10. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
[No Abstract] [Full Text] [Related]
12. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of adult t(4;11)(q21;q23)-associated acute lymphoblastic leukemia reveals a different signature from pediatric cases.
De Braekeleer E; Douet-Guilbert N; Le Bris MJ; Basinko A; Morel F; De Braekeleer M
Anticancer Res; 2012 Sep; 32(9):3893-9. PubMed ID: 22993334
[TBL] [Abstract][Full Text] [Related]
14. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants.
Fazio G; Bardini M; De Lorenzo P; Grioni A; Quadri M; Pedace L; Corral Abascal L; Palamini S; Palmi C; Buldini B; Vinti L; Parasole R; Barisone E; Zecca M; Favre C; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Biondi A; Cazzaniga G
Blood; 2021 Apr; 137(14):1980-1984. PubMed ID: 33512459
[No Abstract] [Full Text] [Related]
15. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.
Sanjuan-Pla A; Bueno C; Prieto C; Acha P; Stam RW; Marschalek R; Menéndez P
Blood; 2015 Dec; 126(25):2676-85. PubMed ID: 26463423
[TBL] [Abstract][Full Text] [Related]
16. Genome editing-induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion.
Pan F; Sarno J; Jeong J; Yang X; Jager A; Gruber TA; Davis KL; Cleary ML
J Clin Invest; 2024 Jan; 134(1):. PubMed ID: 37917159
[TBL] [Abstract][Full Text] [Related]
17. Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
Mariani RA; Silva M; Caparelli E; Jennings LJ; Yap KL; Leuer KM; Weinstein J; Gong S
J Pediatr Hematol Oncol; 2020 May; 42(4):e258-e261. PubMed ID: 31343482
[TBL] [Abstract][Full Text] [Related]
18. Genetic and Epigenetic Characterization of a Discordant
Russo A; Viberti C; Mareschi K; Casalone E; Guarrera S; Birolo G; Cazzaniga G; Corral L; Trentin L; Basso G; Fagioli F; Matullo G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575904
[TBL] [Abstract][Full Text] [Related]
19. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Klinger M; Kufer P; Stelljes M; Viardot A; Horst HA; Neumann S; Brüggemann M; Ottmann OG; Burmeister T; Wessiepe D; Topp MS; Bargou R
Haematologica; 2017 Apr; 102(4):e132-e135. PubMed ID: 28082340
[No Abstract] [Full Text] [Related]
20. The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.
Ragusa D; Makarov EM; Britten O; Moralli D; Green CM; Tosi S
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1207. PubMed ID: 32721124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
